PDS Biotechnology Corporation · NASDAQ:PDSB
PDS Biotechnology Corporation financial statements
PDS Biotechnology Corporation's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 60.5K | 59.8K | 57.3K | 49.1K | 246.4K | 176.3K | 98.4K | 69.1K | 182.9K | 100.1K |
| Gross profit | -60.5K | -59.8K | -57.3K | -49.1K | -246.4K | -176.3K | -98.4K | -69.1K | -183.0K | -100.0K |
| Research and development | 19.0M | 22.6M | 27.8M | 29.4M | 11.3M | 7.92M | 6.10M | 830.7K | 34.3M | 24.8M |
| Selling, general and administrative | 12.5M | 13.5M | 15.0M | 12.2M | 10.2M | 6.79M | 11.0M | 14.3M | 17.7M | 14.7M |
| Operating income | -31.5M | -36.3M | -43.0M | -41.7M | -21.4M | -14.9M | -21.0M | -3.65M | -52.0M | -39.5M |
| Depreciation and amortization | 21.8K | 21.1K | 17.4K | 86 | 5.36K | 15.6K | 98.4K | 69.1K | 182.9K | 100.1K |
| EBITDA | -31.5M | -36.3M | -43.0M | -41.7M | -21.4M | -14.9M | -20.9M | -3.58M | -51.8M | -39.4M |
| Interest expense | 5.34M | 4.67M | 4.21M | 1.32M | 0 | 0 | 33.6K | 3.60K | 2.18M | 1.20M |
| Income before tax | -35.7M | -38.5M | -44.3M | -42.1M | -21.4M | -14.8M | -7.38M | -3.84M | -53.4M | -40.7M |
| Income tax | -1.17M | -869.2K | -1.41M | -1.20M | -4.52M | 0 | -381.5K | 0 | -2.59M | -1.85M |
| Net income | -34.5M | -37.6M | -42.9M | -40.9M | -16.9M | -14.8M | -7.00M | -3.84M | -50.9M | -38.8M |
| Earnings per share, basic | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | 1.15 | -1.65 | -1.34 |
| Earnings per share, diluted | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | 1.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.7M | 41.7M | 56.6M | 73.8M | 65.2M | 28.8M | 12.2M | 103.7K | 88.1M | 106.4M |
| Receivables | 3.90K | 13.5K | ||||||||
| Current assets | 28.3M | 45.1M | 59.1M | 76.5M | 66.8M | 30.3M | 14.5M | 122.1K | 89.1M | 107.4M |
| Property, plant and equipment | 120.2K | 142.0K | 134.1K | 0 | 86 | 5.44K | 21.1K | 29.5K | 3.42M | 3.42M |
| Total assets | 30.5M | 45.4M | 59.4M | 77.0M | 67.2M | 30.9M | 14.5M | 164.4K | 92.6M | 110.9M |
| Accounts payable | 3.57M | 1.68M | 6.98M | 1.22M | 1.31M | 1.42M | 1.20M | 1.31M | 4.37M | 3.47M |
| Current liabilities | 9.48M | 17.1M | 13.6M | 9.82M | 3.76M | 3.27M | 2.79M | 1.91M | 12.9M | 6.68M |
| Long-term debt | 11.7M | 9.20M | 19.5M | 23.0M | 30.0K | 17.4M | 15.0M | |||
| Total debt | 16.9M | 21.8M | 23.9M | 23.5M | 490.4K | 610.3K | 30.0K | 20.5M | 15.0M | |
| Total liabilities | 21.2M | 26.4M | 33.3M | 33.0M | 3.99M | 3.76M | 2.79M | 2.23M | 30.2M | 21.6M |
| Shareholders' equity | 9.25M | 19.0M | 26.1M | 44.0M | 63.2M | 27.1M | 11.7M | -2.07M | -609.5K | 89.3M |
| Shares outstanding | 54.9M | 38.0M | 33.1M | 30.2M | 28.4M | 22.3M | 5.28M | 3.42M | 30.9M | 28.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -27.8M | -35.0M | -33.6M | -25.7M | -12.5M | -13.1M | -18.1M | -1.57M | -40.7M | -32.2M |
| Capital spending | 0 | -29.0K | 0 | -4 | -4 | -5 | -1 | 0 | -188.7K | -686.7K |
| Free cash flow | -27.8M | -35.1M | -33.6M | -25.7M | -12.5M | -13.1M | -18.1M | -1.57M | -40.9M | -32.9M |
| Cash from investing | 0 | -29.0K | 0 | 0 | 29.4M | 0 | -188.7K | -686.7K | ||
| Cash from financing | 12.8M | 20.2M | 16.4M | 34.3M | 48.9M | 29.8M | 750.0K | 1.50M | 22.6M | 9.08M |
| Dividends paid | -271 | |||||||||
| Share buybacks | -271 | 29.8M | 750.0K | 721.2K | 17.6M | 315.0K | ||||
| Change in cash | -15.0M | -14.9M | -17.3M | 8.58M | 36.4M | 16.7M | 12.1M | -53.4M | -18.3M | -23.8M |